Publisher Correction to: delivery systems of CRISPR/Cas9-based cancer gene therapy
In the original version of this article [1], published on 18 December 2018, there was 1 incorrect author name.
Main Authors: | Alessio Biagioni, Anna Laurenzana, Francesca Margheri, Anastasia Chillà, Gabriella Fibbi, Mario Del Rosso |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2019-05-01
|
Series: | Journal of Biological Engineering |
Online Access: | http://link.springer.com/article/10.1186/s13036-019-0169-0 |
Similar Items
-
Type II CRISPR/Cas9 approach in the oncological therapy
by: A. Biagioni, et al.
Published: (2017-06-01) -
Mature and progenitor endothelial cells perform angiogenesis also under protease inhibition: the amoeboid angiogenesis
by: Anastasia Chillà, et al.
Published: (2018-04-01) -
CRISPR/Cas9 uPAR Gene Knockout Results in Tumor Growth Inhibition, EGFR Downregulation and Induction of Stemness Markers in Melanoma and Colon Carcinoma Cell Lines
by: Alessio Biagioni, et al.
Published: (2021-05-01) -
uPAR Knockout Results in a Deep Glycolytic and OXPHOS Reprogramming in Melanoma and Colon Carcinoma Cell Lines
by: Alessio Biagioni, et al.
Published: (2020-01-01) -
EGFR/uPAR interaction as druggable target to overcome vemurafenib acquired resistance in melanoma cellsResearch in context
by: Anna Laurenzana, et al.
Published: (2019-01-01)